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Aim: To audit monthly variations in [IRT] corresponding to the 98, 99 and 99.9%
newborn screening cut-off values using two methods.
Methods: [IRT] was analyzed from newborn dried blood spots using the enzyme
immunoassay Quantase Neonatal IRT Screening Assay® (Bio-Rad Laboratories,
Europe Ltd, Perth, Scotland, UK). The number of newborns identiﬁed for follow-
up using [IRT] correlating to the top 2, 1 and 0.1% were calculated on a monthly
basis then compared to a ﬁxed cut-off value corresponding to the cumulative results
for one year.
Results: For the 98% threshold, monthly [IRT] ranged from 66 to 86mg/L whereas
the ﬁxed cut-off was 76mg/L. These approaches both resulted in the identiﬁcation
of 326 newborns. Monthly [IRT] ranged from 76 to 112mg/L whereas the ﬁxed
cut-off was 94mg/L for the 99% threshold resulting in the identiﬁcation of 166
and 155 newborns, respectively. At the 99.9% threshold, monthly [IRT] ranged
from 110 to 230mg/L whereas the ﬁxed cut-off was 157mg/L, which resulted in
the identiﬁcation of 21 and 13 newborns, respectively. No seasonal variation was
noted.
Conclusion: The number of newborns identiﬁed for follow-up is inﬂuenced by the
method used to calculate the newborn screening thresholds for [IRT].
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After 1998 an increasing number of lately diagnosed CF cases led us to initiate a
pilot newborn screening (NBS) project in the Czech Republic (II/2005-XII/2006).
The aim of our study was to compare clinical development of 11 patients diagnosed
by NBS with the cohort of 95 patients diagnosed clinically. Both groups have
been followed-up at Prague CF Centre (1999–2006). We have analysed age at
diagnosis, CFTR genotype, nutritional status, lung function and lung radiological
changes. Within the clinically diagnosed group median age at diagnosis (MADg)
was 1.5 years. Body height (SDS) at diagnosis was −1.0+1.0 SD and body weight
−1.27+1.1 SD. Nutritional status was worse in children diagnosed during the ﬁrst
year of life (median weight −2 SD). Although due to intensive treatment mean
FEV1 at the age of 5 years was favourable (92.7+18.7% p.v.), 17% of patients were
diagnosed late, i.e. with obstruction of the airways and irreversible lung damage. In
the NBS group MADg was 37 days. Interestingly, 4 cases were simultaneously
diagnosed clinically elsewhere. Two patients were compound heterozygotes for
F508del with a mild (Class IV-V) mutation: I336K / 3849+10kb C>T. Body height
at diagnosis was −0.8+0.6 SD and body weight −0.6+0.6 SD. Further development
of the screened patients is favourable with mean weight at 6 months and 1 year
(−0.3 SD) promising an overall better outcome in these cases. Although, our data are
preliminary these results suggest that NBS in the conditions of the Czech Republic
is an effective tool for early CF detection. According to our experience it may
improve the course of the disease at least in 17% of Czech CF patients.
Supported by: IGA 8236−3, VZ 64203.
365 Cystic ﬁbrosis newborn screening in the Czech Republic:
overview of a pilot study
M. Balascakova1, A. Holubova1, V. Skalicka1, P. Kracmar2, V. Vavrova1,
D. Zemkova1, J. Camajova1, T. Piskackova1, M. Macek Jr.1, F. Votava2. 1Cystic
Fibrosis Centre, UH Motol and Charles University, Prague, Czech Republic; 2Dpt.
of Pediatric, UH FNKV and Charles University, Prague, Czech Republic
CF is the most common autosomal recesive, potentially lethal disoder, affecting
approximately ~1:2700 newborns in the Czech Republic (CZ). A signiﬁcant delay
of the age at diagnosis (ADg) in our country (ADg prior to 1998/median: 0.58 years/
signiﬁcantly increased from 1999 to 2005 (median 1.2 years); p = 0.036) led us to
initiate a pilot newborn screening (NBS) for CF (II/2005 – XI/2006) covering 62%
of all Czech newborns. The major aim of the two tier (IRT/DNA) NBS was to assess
its feasibility and efﬁcacy in the conditions of our country. The level of immunore-
active trypsinogen (IRT) was measured in 76,438 Guthrie cards. Concentration of
IRT above the adjusted cut off level of 75 ng/ml was found in 800 cases (1.05%
of the total). In these high risk cases we examined the most common, population
speciﬁc mutations, of CFTR gene covering approximately 84% of all CF alleles.
A total of 12 cases with CF were identiﬁed, with the median ADg. of 38 days.
Furthermore, we detected 53 newborns with 1 CFTR allele. These were subjected
to follow-up sweat tests. Thus far, 45x were negative – unaffected heterozygotes
and one was borderline, which requires long-term monitoring. The ascertained
incidence of 1: 6369 newborns, using NBS data only, was signiﬁcantly lower than
the epidemiologically established incidence. Nevertheless, when respective prenatal
diagnosis data were taken into consideration an adjusted incidence increased to
1:3500 newborns. Overall, our study proved that NBS is a feasible and efﬁcacious
tool for uniform and early diagnosis of CF.
Supported by: MZCR 1A/8236−3 and VZFNM 64203 (6112).
366 Neonatal cystic ﬁbrosis screening in Russian Federation
V.D. Tolstova, N.I. Kapranov, N.Y. Kashirskaya. Cystic ﬁbrosis, Research Centre
for Medical Genetics RAMS, Moscow, Russian Federation
Objective: Total screening of newborns has become one of the important methods
of cystic ﬁbrosis (CF) early detection, which allows timely start the treatment that,
in turn, increases the life span and the quality of life of the patients.
Methods: Since June 2006, the screening of newborns has been conducting in
several regions of Russian Federation (RF). At the ﬁrst stage of examination, the
immuno-reactive trypcine content in the dried blood spot is determined. In the
newborns with the increased content (>70 ng/mL), repeated determination is made
during the fourth week of life. If the retest is also positive (>40 ng/mL), the newborn
is forwarded to the CF Center. Proof of the diagnosis is based on the sweat test.
If the sweat test is positive (>60mmol/L in classical test or >80mmol/L using
determination of the sweat conductivity by Nanoduct, Macroduct+Sweat-Check
(Wescor) systems) the CF diagnosis is considered to be conﬁrmed. If the result
of the sweat test is border-line (40−60mmol/L and 60−80mmol/L, respectively)
the DNA test is conducted at 23 widespread in RF CF mutations.
Results: From June to December 2006, 63082 newborns were examinated in
Moscow. 408 had neonatal hypertrypcinogenemia. Repeated test was positive in
41 cases. Based on the sweat test, CF was conﬁrmed in 5 cases. The signs of
pancreatic deﬁciency were noticed in 5, and respiratory syndrome in 4 cases. Three
families denied the examination at the CF Center.
Discussion: Since Jan 2007 the screening program will be performed in all regions
of RF. It will allow (i) determine the true frequency of the disease in various regions,
(ii) provide in time diagnostics, (iii) improve CF progress and prognosis. Our data
proves the frequency of CF in RF which has been previously determined to be
1:12300 newborns.
